- Home
- ROIV vs CHKP Comparison
ROIV vs CHKP Comparison
Compare ROIV & CHKP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | CHKP |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United Kingdom | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.6B | 19.4B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | ROIV | CHKP |
|---|---|---|
| Price | $26.32 | $171.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 22 |
| Target Price | $27.44 | ★ $218.76 |
| AVG Volume (30 Days) | ★ 6.9M | 1.4M |
| Earning Date | 02-06-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.95 |
| EPS | N/A | ★ 9.62 |
| Revenue | $13,310,000.00 | ★ $2,725,400,000.00 |
| Revenue This Year | N/A | $8.42 |
| Revenue Next Year | $741.42 | $6.11 |
| P/E Ratio | ★ N/A | $17.83 |
| Revenue Growth | N/A | ★ 6.25 |
| 52 Week Low | $8.73 | $161.00 |
| 52 Week High | $27.94 | $234.36 |
Technical Indicators
Market Signals| Indicator | ROIV | CHKP |
|---|---|---|
| Relative Strength Index (RSI) | 66.81 | 37.44 |
| Support Level | $26.31 | $161.00 |
| Resistance Level | $27.94 | $185.42 |
| Average True Range (ATR) | 0.97 | 5.84 |
| MACD | 0.46 | -0.86 |
| Stochastic Oscillator | 79.45 | 30.29 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CHKP Check Point Software Technologies Ltd.
Check Point Software Technologies is a pure-play cybersecurity vendor. The company offers solutions for network, endpoint, cloud, and mobile security in addition to security management. Check Point, a software specialist, sells to enterprises, businesses, and consumers. Around 50% of revenue is generated in Europe, the Middle East, and Africa, 40% from the Americas, and 10% from the Asia-Pacific region. The firm, based in Tel Aviv, Israel, was founded in 1993 and has about 5,000 employees.